{
    "clinical_study": {
        "@rank": "82322", 
        "arm_group": [
            {
                "arm_group_label": "CJ Imatinib 200mg", 
                "arm_group_type": "Experimental", 
                "description": "1 tablet(200mg) a day,PO,QD"
            }, 
            {
                "arm_group_label": "Gleevec 100mg", 
                "arm_group_type": "Active Comparator", 
                "description": "2 tablet(100mg) a day,PO,QD"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the pharmacokinetics of CJ Imatinib mesylate tablet 1 x\n      200mg compared with Gleevec film-coated tablet 2 x 100mg in healthy male volunteers."
        }, 
        "brief_title": "to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male volunteers in the age between 20 and 55 years old\n\n          -  Judged to be in good health on the basis of their vital sign, ECG, physical   exam\n             and routine laboratory data\n\n          -  Body Mass Index (BMI) in the range of 18.5 to 27 kg/m2\n\n          -  Available for the entire study period\n\n          -  Willing to adhere to protocol requirements and sign a informed consent form\n\n        Exclusion Criteria:\n\n          -  History of clinically significant hepatic, renal, neurology, psychiatric, pulmonary,\n             endocrine, hematologic, cardiovascular disease\n\n          -  Clinically significant vital sign\n\n               -  SBP(Systolic Blood Pressure) \u2264 90 mmHg or SBP \u2265 140 mmHg\n\n               -  DBP(Diastolic Blood Pressure) \u2264 60 mmHg or DBP \u2265 100 mmHg\n\n          -  History of surgery except or gastrointestinal disease which might significantly\n             change absorption of medicines\n\n          -  History of clinically significant allergies, including imatinib\n\n          -  Clinical laboratory test values are outside the accepted normal range\n\n               -  AST(ASpartate Transaminase), ALT(ALanine Transaminase)( > 1.5 times to normal\n                  range\n\n               -  Estimated GFR(Glomerular Filtration Rate) < 80 mL/min\n\n          -  History of caffeine, alcohol, smoking abuse\n\n               -  caffeine > 4 cups/day\n\n               -  grapefruit juice  > 4 cups/day\n\n               -  smoking > 20 cigarettes/day\n\n               -  alcohol > 140g/week\n\n          -  Participated in a previous clinical trial within 3 months prior to dosing\n\n          -  Donated blood within 60 days prior to dosing\n\n          -  Use of prescription only medicine and oriental medicine within the 14 days before\n             dosing or use of non-prescription medicine within the 10 days before dosing\n\n          -  Subjects considered as unsuitable based on medical judgement by investigators"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926548", 
            "org_study_id": "CJ_IMM_101"
        }, 
        "intervention": [
            {
                "arm_group_label": "CJ Imatinib 200mg", 
                "intervention_name": "CJ Imatinib mesylate tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Gleevec 100mg", 
                "intervention_name": "Gleevec film-coated tablet 2 x 100mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Imatinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pharmacokinetics", 
            "Safety"
        ], 
        "lastchanged_date": "August 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-710"
                }, 
                "name": "Samsung Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open-label, Randomized, Single-dose, 2-way Crossover Study to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Administration of IP : 1day", 
            "measure": "maximum concentration,  Area under the concentration-time curve from zero to infinity", 
            "safety_issue": "No", 
            "time_frame": "Blood sampling up to 72hs post dose(16 times)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926548"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Administration of IP : 1 day", 
            "measure": "Time to peak concentration, t1/2, Area under the concentration-time curve from zero to infinity", 
            "safety_issue": "No", 
            "time_frame": "Blood sampling up to 72hs post dose(16 times)."
        }, 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}